Icon (NASDAQ:ICLR) Releases FY 2026 Earnings Guidance

Icon (NASDAQ:ICLR) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 10.000-11.000 for the period, compared to the consensus estimate of 11.330. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $7.9 billion.

Wall Street Analyst Weigh In

ICLR has been the subject of several research analyst reports. Bank of America reiterated an “underperform” rating and issued a $105.00 price objective on shares of Icon in a research note on Wednesday. Citigroup lowered their price objective on shares of Icon from $200.00 to $120.00 and set a “neutral” rating for the company in a research note on Wednesday, March 11th. Rothschild & Co Redburn set a $100.00 price objective on shares of Icon and gave the company a “neutral” rating in a research note on Tuesday, February 17th. Weiss Ratings lowered shares of Icon from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. Finally, Jefferies Financial Group set a $135.00 price objective on shares of Icon and gave the company a “buy” rating in a research note on Monday, February 23rd. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $147.67.

Icon Trading Up 4.0%

Shares of NASDAQ:ICLR traded up $4.60 during mid-day trading on Wednesday, hitting $118.45. The company had a trading volume of 1,759,245 shares, compared to its average volume of 1,582,337. The firm has a fifty day moving average price of $111.14 and a 200 day moving average price of $141.95. The company has a market capitalization of $9.57 billion, a PE ratio of 16.03, a price-to-earnings-growth ratio of 3.05 and a beta of 1.23. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.06 and a quick ratio of 1.06. Icon has a one year low of $66.57 and a one year high of $211.00.

Institutional Trading of Icon

A number of hedge funds and other institutional investors have recently bought and sold shares of ICLR. Harris Associates L P bought a new stake in Icon during the 2nd quarter valued at $238,256,000. Wellington Management Group LLP increased its stake in Icon by 26.6% during the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after purchasing an additional 975,268 shares in the last quarter. Boston Partners increased its stake in Icon by 1,207.3% during the 3rd quarter. Boston Partners now owns 739,135 shares of the medical research company’s stock valued at $129,372,000 after purchasing an additional 682,597 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in Icon during the 2nd quarter valued at $94,814,000. Finally, JPMorgan Chase & Co. increased its stake in Icon by 453.0% during the 4th quarter. JPMorgan Chase & Co. now owns 767,924 shares of the medical research company’s stock valued at $139,931,000 after purchasing an additional 629,056 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.